Toolkit
Email Alert
Sign up to join Advicenne’s Press Releases diffusion list
Contacts
Advicenne
22 Rue de la Paix – 3ème étage
F-75002 Paris, France
+33 4 66 05 54 20
investors@advicenne.com
Financial Communications
NewCap
Emmanuel Huynh & Alexia Faure
+33 1 44 71 94 94
advicenne@newcap.eu
Committee charters
Members of the Board of Directors and Committees
26th of May 2020
| Board of Directors | Audit Committee | Appointment and Remuneration Committee | |
| David Horn Solomon | x President | ||
| André Ulmann | x | ||
| Philippe Boucheron | x | x President | |
| Hege Hellstrom | x | ||
| Charlotte Sibley | x | x | |
| Thibaut Roulon | x | x | |
| Catherine Dunand | x | x President | x |
| Jean-Michel Petit | x | x |
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2019 Advicenne